|
Event verbatim [preferred term] (related symptoms if any separated by commas), needle reusage [multiple use of single-use product], left leg infection [localised infection], possible blood clotting [thrombosis].Case description: study id: patient assistance program study description: the novo nordisk diabetes patient assistance program is a program for patients that qualify for financial assistance pursuant to financial guidelines as established by novo nordisk.Patients will be evaluated for the program against the criteria established by novo nordisk.This serious solicited report from the united states was reported by a consumer as "needle reusage(needle reusage)" with an unspecified onset date , "left leg infection(leg infection)" with an unspecified onset date , "possible blood clotting(clot blood)" with an unspecified onset date and concerned a male patient (born in 1953) who was treated with novofine 32g 4mm (needle) from unknown start date for "diabetes mellitus".Current condition: diabetes (type and duration was not reported).Concomitant medications included - tresiba flextouch u100(insulin degludec 100 iu/ml) solution for injection, 100 iu/ml, tresiba flextouch u200(insulin degludec) solution for injection, 200 iu/ml.On an unspecified date, the patient reported of reusing the needles.As a result the patient had an infection in the left leg with symptoms of pain and extreme swelling.As treatment the patient applied ice and elevated it.It was also suspected that the patient had possible blood clotting.A doppler reading test was done but results were not provided.On an unspecified date, patient's blood test and urine analysis were performed, results not reported.Batch numbers: novofine 32g 4mm: 21j20n.Action taken to novofine 32g 4mm was not reported.The outcome for the event "needle reusage(needle reusage)" was not reported.The outcome for the event "left leg infection(leg infection)" was unknown.The outcome for the event "possible blood clotting(clot blood)" was not reported.Reporter's causality (novofine 32g 4mm): needle reusage(needle reusage) : unknown, left leg infection(leg infection) : unknown, possible blood clotting(clot blood) : unknown.Company's causality (novofine 32g 4mm): needle reusage(needle reusage) : possible, left leg infection(leg infection) : unlikely, possible blood clotting(clot blood) : unlikely.Since last submission the case has been updated with the following: batch number, manufacturing date and expiry date updated.Narrative updated accordingly.Final manufacturer's comment: on (b)(6) 2022: the suspected device (novofine plus 4mm (32g)) has not been returned to novo nordisk a/s for the investigation.Batch number of devices is available now.Batch trend analysis or reference sample analysis will be performed.No confounding factors identified.With the available limited information regarding the handling of the suspected device, it is not possible to identify a clear root cause in relation to functionality of novofine plus 4mm (32g).Reusing the needle could have contributed to localised infection at the injection site.Manufacturing site is confirmed with batch number to be 9681822, report 9681821-2022-00028 will be further reported.Continued: evaluation summary novofine® plus 32g x 4mm - batch unknown.No investigation was possible, because neither sample nor batch number was available.If possible, please forward the reported product(s) for further investigations.
|
|
Case description: it was discovered that the reported event did not occur with the use of suspect product "novofine 4mm needle" and updated event "gout" was a medical history of the patient.Therefore, the case would be de-activated after this submission.Final manufacturer's comment: 31-may-2022: the case will be a down graded report.Upon follow up, it was found that limb swelling, thrombosis and leg infections are due to underlying medical condition, gout.The reported clinical events are not related needle or needle reusage.Since previously the case was submitted as "reportable final incident", the case would be de-activated after this submission.
|